Effects of a chromogranin-derived peptide (CgA 47-66) in the writhing nociceptive response induced by acetic acid in rats

Regulatory Peptides

Volumn 119, Issue 3, 2004, Pages 199-207

  Ghia, Jean Eric ^a   Crenner, Francis ^a   Metz Boutigue, Marie Hélène ^b   Aunis, Dominique ^b   Angel, Fabielle ^a  

^a INSERM   (France)

^b CENTRE DE NEUROCHIMIE   (France)

Author keywords

47 66; AA; acetic acid; calcitonin gene related peptide; CgA; CgA 47 66; CgA 7 57; CgA47 66; CGRP; Chromogranin; chromogranin A 47 66 peptide; chromogranin A 47 66, modified peptide; chromogranin A 7 57 peptide; CRF; Pain; SP; substance P; Writhing test

Indexed keywords

ACETIC ACID; CALCITONIN GENE RELATED PEPTIDE; CHROMOGRANIN A; CHROMOGRANIN A [47-66]; CORTICOTROPIN RELEASING FACTOR[9-41]; DILTIAZEM; INDOMETACIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ABDOMEN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; HYPOTHESIS; INFLAMMATION; INJECTION; MALE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; WRITHING TEST;

ACETIC ACID; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CARDIOVASCULAR AGENTS; CHROMOGRANIN A; CHROMOGRANINS; CORTICOTROPIN-RELEASING HORMONE; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOMETHACIN; MALE; PAIN; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SUBSTANCE P;

ANIMALIA;

EID: 2142639384     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.02.014     Document Type: Article

References (48)

1. Simon J.P., Aunis D. Biochemistry of the chromogranin A protein family. Biochem. J. 262(1):1989;1-13
2. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 49(3):1992;497-528
3. Helle K.B., Reed R.K., Pihl K.E., Serck-Hanssen G. Osmotic proprieties of the chromogranins and relation to osmotic pressure in catecholamine storage granules. Acta Physiol. Scand. 123(1):1985;21-33
4. Metz-Boutigue M.H., Garcia-Sablone P., Hogue-Angeletti R., Aunis D. Intracellular and extracellular processing of chromogranin A. Eur. J. Biochem. 214:1993;247-257
5. Kanno T., Asada N., Yanase H., Iwanaga T., Ozaki T., Nishikawa Y., et al. Salivary secretion of highly concentrated chromogranin A in response to noradrenaline and acetylcholine in isolated and perfused rat submandibular glands. Exp. Physiol. 84:1999;1073-1083
6. Gauweiler B., Weihe E., Hartschuh W., Yanaihara N. Presence and coexistence of chromogranin A and multiple neuropeptides in Merkel cells of mammalian oral mucosa. Neurosci. Lett. 89(2):1988;121-126
7. D'Este L., Renda T. Phylogenetic study on distribution and chromogranin/secretogranin content of histamine immunoreactive elements in the gut. Ital. J. Anat. Embryol. 100(Suppl. 1):1995;403-410
8. Waldum H.L., Syversen U. Chromogranin A (CGA) and the enterochromaffin-like (ECL) cell. Adv. Exp. Med. Biol. 482:2000;361-367
9. Lugardon K., Raffner R., Goumon Y., Corti A., Delmas A., Bulet P., et al. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J. Biol. Chem. 275(15):2000;10745-10753
10. Tota B., Mazza R., Angelone T., Nullans G., Metz-Boutigue M.H., Aunis D., et al. Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul. Pept. 114(2-3):2003;123-130
11. Omura Y. Treatment of acute or chronic severe, intraitable pain and other intractable medical problems associated with unrecognized viral or bacterial infection: Part I. Acupunct. Electro-Ther. Res. 15(1):1990;51-59
12. Menetrey D., Gannon A., Levine J.D., Basbaum A.I. Expression of c-fos protein in interneurons and projection neurons of the rat spinal cord in response to noxious somatic, articular, and visceral stimulation. J. Comp. Neurol. 285(2):1989 (Jul. 8);177-195
13. Koster R., Anderson M., De Beer E.J. Acetic acid for analgesic screening. Fed. Proc. 18:1959;412
14. Merrifield R.B. Solid phase peptide synthesis. Synthesis of a tetrapeptide. J. Am. Chem. Soc. (85):1963;2149-2154
15. Goumon Y., Strub J.M., Moniatte M., Nullans G., Poteur L., Hubert P., et al. The C-terminal bisphosphorylated proenkephalin-A-(209-237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Eur. J. Biochem. 235(3):1996;516-525
16. Chung K.M., Choi S.S., Han K.J., Han E.J., Lee H.K., Suh H.W. Antinociceptive effects of methysergide in various pain models. Pharmacology. 69(2):2003;93-101
17. Ikeda Y., Ueno A., Naraba H., Oh-ishi S. Involvement of vanilloid receptor VR1 and prostanoids in the acid-induced writhing responses of mice. Life Sci. 69(24):2001;2911-2919
18. Heinrichs S.C., Tache Y. Therapeutic potential of CRF receptor antagonists: a gut-brain perspective. Expert Opin. Investig. Drugs. 10(4):2001;647-659
19. Koob G.F. Stress, corticotropin-releasing factor, and drug addiction. Ann. N.Y. Acad. Sci. 897:1999;27-45
20. Dautzenberg F.M., Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23(2):2002;71-77
21. Schafer M., Carter L., Stein C. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc. Natl. Acad. Sci. U. S. A. 91(10):1994;4219-4223
22. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43(4):1991;425-473
23. Lariviere W.R., Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain. 84(1):2000;1-12
24. Schafer M., Mousa S.A., Stein C. Corticotropin-releasing factor in antinociception and inflammation. Eur. J. Pharmacol. 323(1):1997;1-10
25. Karalis K., Muglia L., Bae D., Hilderbrand H., Majzoub J. CRH and the immune system. J. Neuroimmunol. 72(2):1997;131-136
26. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U. S. A. 90(19):1993;8967-8971
27. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U. S. A. 92(3):1995;836-840
28. Shen Z., Ekelund M., Sundler F. Immunocytochemical evidence for chromogranin A and B in neuronal elements in human gut. Regul. Pept. 51:1994;229-236
29. Sanchez M.M. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in non human primate brain. J. Comp. Neurol. 408:1999;365-377
30. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428(2):2000;191-212
31. Million M., Sahchez-Watts G., Saunders P., Miampamba M., Wang L., Qxhwartz D., et al. CRF receptor subtypes 1 and 2 are expressed in the colonic tissue of the rat. Gastroenterology. 112(4 Suppl.):2002;A524
32. Chalmers D.T., Lovenberg T.W., De Souza E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific sub-cortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15:1995;6340-6350
33. Wei E.T., Kiang J.G., Buchan P., Smith T.W. Corticotropin-releasing factor inhibits neurogenic plasma extravasation in the rat paw. J. Pharmacol. Exp. Ther. 238(3):1986;783-787
34. Hargreaves K.M., Mueller G.P., Dubner R., Goldstein D., Dionne R.A. Corticotropin-releasing factor (CRF) produces analgesia in humans and rats. Brain Res. 422(1):1987;154-157
35. Cabot P.J. Immune-derived opioids and peripheral antinociception. Clin. Exp. Pharmacol. Physiol. 28(3):2001;230-232
36. Esposito P., Gheorghe D., Kandere K., Pang X., Connolly R., Jacobson S., et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res. 888(1):2001;117-127
37. Su X., Wachtel R.E., Gebhart G.F. Inhibition of calcium currents in rat colon sensory neurons by K- but not mu- or delta-opioids. J. Neurophysiol. 80(6):1998;3112-3119
38. Dogrul A., Yesilyurt O. Effects of intrathecally administered aminoglycoside antibiotics, calcium-channel blockers, nickel and calcium on acetic acid-induced writhing test in mice. Gen. Pharmacol. 30(4):1998;613-616
39. Bartho L., Lenard L. Jr., Lazar Z., Maggi C.A. Connections between P2 purinoceptors and capsaicin-sensitive afferents in the intestine and other tissues. Eur. J. Pharmacol. 375(1-3):1999;203-210
40. Julia V., Bueno L. Tachykininergic mediation of viscerosensitive responses to acute inflammation in rats: role of CGRP. Am. J. Physiol. 272(1 Pt. 1):1997;G141-G146
41. Lynn B. Neurogenic inflammation caused by cutaneous polymodal receptors. Prog. Brain Res. 113:1996;361-368
42. Friese N., Diop L., Chevalier E., Angel F., Riviere P.J., Dahl S.G. Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul. Pept. 70(1):1997;1-7
43. Laird J.M., Olivar T., Roza C., De Felipe C., Hunt S.P., Cervero F. Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience. 98(2):2000;345-352
44. Plourde V., St-Pierre S., Quirion R. Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. Am. J. Physiol. 273(1 Pt. 1):1997;G191-G196
45. Roza C., Reeh P.W., Substance P. Calcitonin gene related peptide and PGE2 co-released from the mouse colon: a new model to study nociceptive and inflammatory responses in viscera, in vitro. Pain. 93(3):2001;213-219
46. Di Carlo G., Izzo A.A. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin. Investig. Drugs. 12(1):2003;39-49
47. Someya A., Horie S., Murayama T. Arachidonic acid release and prostaglandin F(2alpha) formation induced by anandamide and capsaicin in PC12 cells. Eur. J. Pharmacol. 450(2):2002;131
48. Franco-Cereceda A. Prostaglandins and CGRP release from cardiac sensory nerves. Naunyn-Schmiedeberg's Arch. Pharmacol. 340(2):1989;180-184